30 April 2021 - Today, eleven subcutaneous TNF-alpha inhibitors are included in the high-cost protection. ...
21 April 2021 - TLV has produced a health economic assessment for the regions for the drug Qarziba (dinutuximab beta). ...
19 April 2021 - TLV has produced a health economic assessment for the regions for the drug Darzalex in combination with ...
26 March 2021 - The Swedish Dental and Pharmaceutical Benefits Agency, TLV, grants a subsidy for the drug Melatonin AGB ...
25 March 2021 - The Swedish Dental and Pharmaceutical Benefits Agency, TLV, says no to subsidising the drugs Kaftrio and Kalydeco ...
16 February 2021 - The Government has commissioned the Swedish Dental and Pharmaceutical Benefits Agency, TLV, to implement measures to reduce ...
18 December 2020 - During the autumn, the Swedish Dental and Pharmaceutical Benefits Agency, TLV, reconsidered the subsidy of the hepatitis ...
4 December 2020 - TLV has produced a health economic assessment for the regions for Beovu (brolucizumab). ...
26 November 2020 - Takhzyro (lanadelumab) is a subcutaneous injection intended for routine prevention of recurrent hereditary seizures, angioedema in patients ...
25 November 2020 - TLV has reconsidered the subsidy for Rinvoq (upadacitinib monohydrate) and decided that the drug should continue to ...
6 November 2020 - TLV has performed an additional analysis of Kyprolis (carfilzomib) when used in combination with lenalidomide and dexamethasone ...
29 October 2020 - The regions have submitted an application for a price change for Cimzia (certolizumab pegol) and Simponi (golimumab). ...
28 October 2020 - TLV starts a reconsideration to investigate the current subsidy status for Cosentyx. ...
23 October 2020 - The current side agreements for hepatitis C drugs signed by the companies and the regions expire in ...
23 October 2020 - For the first time in Sweden, a cancer drug against a specific genetic change, instead of against ...